Certara has announced that it has acquired a range of modelling and simulation technology assets from In Silico Biosciences
Certara, a provider of software for model-informed drug development and decision support leader, has announced the launch of Hasharc, its decentralised application (DApp) for healthcare, built in conjunction with the Hedera public Distributed Ledger Technology (DLT)
Certara, a provider of model-informed drug development and decision support software, has announced the launch of BaseCase Data Manager, which allows clients to build interactive, data-driven mobile tools using real-world data sources, such as healthcare claims, costs, quality, outcomes, and population data.
Certara, a provider of global model-informed drug development software, has announced the launch of version 19.6 of D360, its scientific informatics platform for drug discovery and development. Designed to meet the scientific researcher’s need to quickly access, understand and share data, the D360 platform is delivered through its toolkits – small molecule discovery, biologics discovery, and pre-clinical translation – each tailored to meet specific research goals. This latest version of D360 takes its name from its release date; it is the 2019 mid-year release.
Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that it has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve worldwide equity in health. CGH is a new product development innovation practice inspired by Certara’s drug development and scientific due diligence work for the Bill & Melinda Gates Foundation.
Certara has announced the introduction of Certara Integral, its data repository for collecting, managing, and storing multiple types of data sets for analysis, sharing and reporting of clinical pharmacology, pharmacometrics and other relevant clinical data.
Certara, a provider of model-informed drug development, regulatory science, real-world evidence and market access services, has announced four senior executive appointments in its Simcyp division
Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 19.1 of its flagship scientific informatics platform D360.
D360 v19.1 expands the platform’s capabilities for biologists and biologics scientists, deepens support for small molecule chemistry, and provides workflow enhancements based on community feedback. This latest version of D360 takes its name from its calendar release date; this is the first new release in 2019.
Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 18 of its Simcyp Population-based Simulator
Certara has announced that Craig Rayner, PharmD, MBA, senior vice president, integrated drug development with Certara Strategic Consulting, has been awarded the 2018 Distinguished Alumni Award for the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University.
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
